Precision NanoSystems Inc.

As part of the NanoAssemblr® Platform, the NanoAssemblr® Ignite™ enables the rapid and controlled manufacture of nanomedicines. Conceived for the development of transformative medicines at the bench scale, the Ignite system has been:

Designed with the End in Mind

Develop a robust, scalable process from the earliest stage  A drug product is produced by adhering to the unit process steps necessary for clinical manufacturing. Ignite simplifies the transition into clinical programs by incorporating these fundamental process steps for scale up in the earliest stages of pre-clinical by modelling clinical manufacturing processes at small volumes, costs are reduced, scale up is derisked, and timelines are accelerated.

Designed for the Future

Let technology keep pace with your ideas The next generation of gene therapies, vaccines, and targeted medicines are now achievable with the automated, multi-step synthesis made possible with Ignite. NxGen microfluidic technology, together with Ignite’s three-pump format, provide the basis for expansion to enable new, more sophisticated manufacturing capabilities. 

Designed to Maximize Time

Manufacturing processes should not be long or complex. Ignite lowers the barrier to developing transformative medicines by providing a simple, precise, and fast platform, allowing you to focus on what matters—bringing solutions to patients.

Download our brochure here. 

Explore innovative nanomedicine formulations and create revolutionary medicines with the Spark’s scalable and robust microfluidic system, with minimal consumption of starting materials. The Spark system is designed to be seamlessly integrated with in vitro screening workflows: create on-demand formulations in a sterile biosafety hood and apply them directly to cells in culture. The Spark instrument streamlines the screening of various formulation parameters for novel excipients and nanoparticle cargoes. It may also be used in conjunction with PNI’s line of Spark Transfection Kits to formulate particles for in vitro nucleic acid delivery.

Explore Novel Genetic Medicine Formulations

Transformative medicines start with novel materials that can be costly or in limited supply. The Spark is ideal for screening novel genetic medicine formulations because it provides:

Unmatched Sample Recovery

Advanced microfluidics allows microliter formulation volumes with near-complete sample recovery. 

Intuitive Operation

Simply pipette starting materials into wells, push a button and pipetter completed formulations out. 

Rapid Production

The Spark formulation process requires less than 10 seconds allowing hundres of formulations to be made in hours. 

Robust Process

Electronic control minimizes batch-to-batch and user variability. 

Workflow Integration

The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture. 

Scalable

NxGen microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development. 

The NanoAssemblr® Blaze allows rapid scaling of nanoparticle formulations for late pre-clinical development. The system can manufacture between 10 mL and 10 L of formulation which allows researchers to use the Blaze for preclinical toxicology testing, and for early Chemistry, Manufacturing and Controls (CMC) studies. 

Download our brochure here.